Dr Reddys Labs launch first-wave generic version of Daraprim

On Friday, Dr Reddy's Laboratory informed the bourses that it has launched Pyrimethamine tablets USP, 25 mg, which are therapeutic equivalent and first-wave generic version of Daraprim tablets in US markets. The product is the only rated generic version of Daraprim, which is approved by the United States Food & Drug Administration (USFDA).

Daraprim (pyrimethamine) brand had US sales of approximately US$ 10 million MAT for the most recent twelve months ending in January 2020, according to Quintiles and IMS Health, Inc (IQVIA Health). The drug indicated is used for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.

Dr Reddy's Laboratories Limited is a pharmaceutical company operating in three segments, namely, global generics, pharmaceutical services and active ingredients as well as proprietary products.

At 2 pm on Friday, the stock was trading at Rs 2,873.15, up by 9.55 per cent or Rs 250.40 per share. The 52-week high is recorded at Rs 3,363 and the 52-week low is Rs 2,352 on BSE.